Can Iron Infusions Cause High Blood Pressure?

Iron infusions can cause blood pressure changes, but the effect is not as straightforward as a simple yes or no. In some settings, particularly during hemodialysis, intravenous iron has been linked to modest blood pressure increases. In other contexts, the most commonly reported cardiovascular side effect is actually low blood pressure, not high. The direction and size of any blood pressure shift depend on the iron formulation used, the dose, the speed of infusion, and the patient’s underlying health, making this a question where the details matter more than the headline.

What Happens to Blood Pressure During an Infusion

For most people receiving iron infusions outside of dialysis, large blood pressure swings are uncommon. In a study of 107 patients with chronic kidney disease who received high-dose iron sucrose, average blood pressure barely moved: it started at about 138/75 and ended at roughly 141/76, with no patients needing extra blood pressure medication during or after treatment.¹ That kind of trivial change falls within normal fluctuation and would go unnoticed without a blood pressure cuff.

When blood pressure does change during an iron infusion, it is more often a drop than a spike. A randomized trial comparing oral and intravenous iron in kidney disease patients found that the most frequently reported side effect of the intravenous route was low blood pressure, not high.² This is consistent with what infusion nurses see in day-to-day practice: dizziness or lightheadedness from a mild blood pressure dip is the more typical concern.

That said, some iron formulations carry a recognized hypertension signal. Ferumoxytol, an iron preparation sometimes used as an MRI contrast agent, was associated with a hypertension rate of about 2.4% across pooled safety data, making it the single most commonly reported adverse event for that drug.³ Two to three out of a hundred patients is not common, but it is enough to warrant monitoring.

The Hemodialysis Connection

The clearest signal linking iron infusions to higher blood pressure comes from patients on hemodialysis, a population that receives intravenous iron routinely to counteract the anemia caused by kidney failure and the dialysis process itself. During dialysis, blood pressure normally drifts downward as fluid is removed. Iron infusion appears to blunt that drop, and sometimes reverses it entirely.

In one study of hemodialysis patients, the average blood pressure decrease from the start to the end of a session was about 10 mmHg when no iron was given, but only about 4 mmHg when iron was infused. More striking, roughly a third of dialysis sessions that included iron ended with blood pressure higher than it started, compared to fewer than one in ten control sessions.⁴ That is a meaningful difference for patients whose blood pressure management during dialysis is already a balancing act.

A larger study of 950 outpatient hemodialysis patients reinforced this pattern. Higher doses of iron sucrose were associated with intradialytic hypertension, with doses of 100 mg or more linked to a statistically significant increase in the risk of a blood pressure rise during the session. The same study noted that iron sucrose was also associated with higher systolic blood pressure both during and after dialysis, while simultaneously lowering the risk of the opposite problem: intradialytic blood pressure drops.⁵ In other words, iron nudges the hemodynamic balance upward in this population.

This does not mean that every dialysis patient will see their blood pressure climb. An earlier study of patients with moderate to severe kidney disease who were not yet on dialysis found that only four out of several dozen patients needed their blood pressure medications adjusted after starting intravenous iron.⁶ Those four cases prove it can happen, but they also show that most patients got through treatment without any change to their blood pressure regimen.

Why Iron Could Raise Blood Pressure

The biological explanation for why intravenous iron might push blood pressure upward involves what happens when free iron hits the bloodstream. Iron formulations are designed to release their iron payload slowly and safely, but some amount of loosely bound iron inevitably escapes. This “labile” iron is chemically reactive. It can generate free radicals, molecules that damage the inner lining of blood vessels and interfere with their ability to relax.

A study using ferric saccharate (an older iron formulation) showed that infusion led to a more than fourfold spike in non-transferrin-bound iron, the loosely held form. Within ten minutes, the blood vessels’ ability to dilate in response to blood flow dropped significantly. Superoxide production in the blood jumped by about 70% at 10 minutes and was still elevated by over 50% four hours later.⁷ When blood vessels lose their ability to relax properly, the result is higher resistance to blood flow, and that means higher blood pressure.

Whether this acute vascular stress translates into a lasting problem depends on the formulation. Newer iron preparations are engineered with more stable carbohydrate shells that release iron more gradually, producing less labile iron and potentially less oxidative damage. A trial of ferric derisomaltose, one of the newer formulations, found no evidence of prolonged oxidative stress or inflammation in kidney disease patients over a three-month follow-up period.⁸ There was a modest rise in E-selectin, a marker of endothelial activation, at one and three months, but the main oxidative stress markers stayed flat. That is reassuring, though it does not erase the acute effects that happen in the minutes after any iron hits the bloodstream.

Not All Iron Formulations Are the Same

One of the most important things to understand about intravenous iron and blood pressure is that “iron infusion” is not a single treatment. There are several distinct iron formulations used clinically, and they differ in their carbohydrate coating, molecular weight, how quickly they release iron, and their side effect profiles. The major ones in current use include iron sucrose, ferric carboxymaltose, ferric derisomaltose (also called iron isomaltoside), low-molecular-weight iron dextran, and ferumoxytol.

Iron sucrose is the formulation most studied in the dialysis population and the one most clearly linked to intradialytic blood pressure rises. Ferumoxytol carries the hypertension signal mentioned earlier at around 2.4% of patients. Ferric carboxymaltose and ferric derisomaltose are newer agents that allow higher single doses and faster infusions; a systematic review and meta-analysis examined cardiovascular event rates across these three formulations, including hypertensive and hypotensive events, as part of a composite cardiovascular safety endpoint.⁹ The differences between formulations are not dramatic enough to rank one as clearly “safe” and another as “dangerous” for blood pressure, but they do influence which product a clinician might choose for a patient whose blood pressure is already difficult to control.

Low-molecular-weight iron dextran, which has been used for decades, has its own side effect profile weighted more toward infusion reactions like flushing and allergic-type symptoms than toward blood pressure changes. In pregnant women receiving total-dose infusions of this formulation, mild side effects like palpitations and flushing occurred in about 4% of patients, with no specific signal for hypertension.¹⁰

Infusion Reactions That Mimic Blood Pressure Problems

Some of the blood pressure changes seen during iron infusions are not direct pharmacological effects of the iron at all. They are part of what clinicians call complement activation-related pseudo-allergy, sometimes referred to as a “Fishbane reaction” after the researcher who described it. These reactions can include flushing, chest tightness, back pain, and transient swings in blood pressure in either direction. They look alarming but are generally self-limiting and do not represent true anaphylaxis.

True anaphylactic reactions to modern iron formulations are rare. Expert reviews of intravenous iron safety in kidney disease patients have concluded that hypersensitivity reactions and genuine anaphylaxis occur infrequently, and that the nature of labile-iron-driven reactions is now much better understood than it was when iron dextran dominated the market.¹¹ The practical consequence is that a blood pressure spike during an iron infusion may be part of a transient reaction rather than a sign that the iron itself is raising your baseline blood pressure. Staff at infusion centers are trained to distinguish between the two, which is why vital signs are monitored before, during, and after treatment.

Canadian clinical experts have developed a consensus algorithm for identifying and managing these hypersensitivity reactions, covering preparation, administration, and response protocols.¹² If you have had a reaction during a previous iron infusion, your provider can use a slower rate, a different formulation, or premedication to reduce the chance of a repeat episode.

Long-Term Vascular Concerns with Repeated Infusions

The question of whether iron infusions raise blood pressure becomes more nuanced when you zoom out from a single treatment session to years of repeated dosing. People with chronic conditions like kidney disease, inflammatory bowel disease, or heavy menstrual bleeding may receive iron infusions regularly, and cumulative iron exposure could have effects on blood vessels that a single infusion would not.

In kidney disease patients, repeated iron sucrose administration has been linked to increased levels of soluble adhesion molecules, proteins that indicate the inner lining of blood vessels is inflamed and activated. Cumulative iron dose has also been correlated with greater intima-media thickness, a measurement of how thick the artery wall has become. Thicker artery walls are an early marker of atherosclerosis and are associated with higher cardiovascular risk.¹³

Animal research has explored what chronic iron overload does to the arteries directly. In rats given enough iron to produce overload, aortic pulse wave velocity increased significantly, meaning the arteries became stiffer. Stiffer arteries are a well-established driver of systolic hypertension, particularly in older adults. The stiffening was not caused by the arteries getting physically thicker but rather by changes in wall composition, specifically an increase in collagen content. Treating the iron-overloaded rats with an angiotensin receptor blocker (a common blood pressure drug) prevented both the stiffening and the collagen buildup, suggesting the process runs through the same pathways that conventional hypertension medications target.¹⁴

It is worth stressing that iron overload from infusions and iron overload in a rat model are not the same thing. Clinicians monitor ferritin and transferrin saturation precisely to avoid pushing iron stores into dangerous territory. But the animal data provide a plausible biological road map for how excessive cumulative iron exposure could contribute to stiffened arteries and, eventually, higher blood pressure over time.

Hypophosphatemia and Its Indirect Effects

One under-recognized side effect of certain iron infusions is a drop in blood phosphate levels, called hypophosphatemia. This is particularly associated with ferric carboxymaltose. In a study of patients with heart failure, about 27% developed hypophosphatemia after ferric carboxymaltose infusion, with nearly all of those cases classified as severe. Phosphate levels typically bottomed out around eight days after infusion and returned to normal by about six weeks.¹⁵

Hypophosphatemia does not directly raise blood pressure, but it matters for the broader picture of how you feel after an iron infusion. Symptoms can include fatigue, muscle weakness, and bone pain, and severe cases can cause confusion or cardiac arrhythmias. If you are getting iron infusions to treat fatigue from anemia and then develop fatigue from low phosphate, the treatment can feel like it is not working or even making things worse. This side effect is more specific to ferric carboxymaltose than to other formulations, and if your provider is aware of the risk, they can check phosphate levels and switch to a different iron product if needed.

Pediatric Patients and Young Adults

Parents whose children receive iron infusions for anemia related to kidney disease or other chronic conditions naturally worry about cardiovascular side effects. The available evidence is thin but reassuring. A randomized controlled trial comparing three different iron sucrose maintenance regimens in children, adolescents, and young adults with chronic kidney disease found no differences in adverse effects across the regimens, and all reported side effects were minor.¹⁶ This is a single trial, so it does not rule out rare events, but it aligns with the general clinical experience that iron infusions are well tolerated in younger patients.

Practical Advice If You Are Concerned

If you are scheduled for an iron infusion and worry about your blood pressure, a few things are worth keeping in mind. First, your blood pressure will be measured before and after the infusion as standard practice. If you tend to run high, mention this to the infusion staff so they can monitor more closely and adjust the rate if needed.

Second, the formulation matters. Ask your provider which iron product you are receiving. If you have a history of difficult-to-control blood pressure and are on hemodialysis, the evidence suggests that higher single doses of iron sucrose are more likely to nudge your blood pressure upward during the session. Your nephrologist may opt for smaller, more frequent doses or a different formulation entirely.

Third, a transient blood pressure blip during an infusion is not the same as developing chronic hypertension from iron therapy. Most blood pressure changes observed in studies resolve within minutes to hours. The long-term vascular concerns are more theoretical at this point and apply primarily to patients receiving very large cumulative iron doses over years. For someone getting a one-time or short-course iron infusion for iron-deficiency anemia, the cardiovascular risk is extremely low.

Finally, the reason you are getting the infusion matters too. Untreated iron-deficiency anemia itself strains the cardiovascular system: the heart has to work harder to deliver oxygen with fewer red blood cells, which can raise heart rate, increase cardiac output, and over time contribute to heart enlargement. In many cases, correcting the anemia with iron does more to protect your cardiovascular health than the infusion could plausibly do to harm it.